Interferon alfa-2b, Recombinant for Injection Articles
Russia's hepatitis C virus drug market set to grow 9% annually, reaching $327 million by 2013
3 December 2009
Drug Royalty buys 25% of Peg-Intron royalties
3 September 2007
S-P subsidiary fined $435.0M
29 January 2007
S-P granted EU label change for Intron A
1 May 2006
S-P launches Rebetol oral solution in USA
26 January 2004
Rebetol gets FDA OK for use in children
11 August 2003
S-P's new CEO sets out turnaround plan
19 May 2003
Stock Commentary - Week to Feb 10 - New York
17 February 2003
ICN defending ribavirin patent
11 March 2002
Record revenues reported at ICN
4 March 2002
Japan approves S-P's HCV combination
22 November 2001
Sales flat at Schering-Plough as manufacturing problems persist
23 October 2001
ICN Pharma earnings take a downturn
3 August 2001
FDA approves Rebetol as separate treatment
31 July 2001
Flat 2nd-qtr sales/EPS at Schering-Plough
25 July 2001
S-P looking for royalty refund from ICN
11 July 2001
S-P submits FDA sBLA for Redipen system
5 July 2001
Manufacturing woes hit Schering-Plough
18 April 2001
US Intron-A pharmacy fraud wins convictions
26 February 2001
EU extends Remicade indications
7 February 2001
Schering-Plough EPS increases 14.7%
26 January 2001
ICN profit warnings for 2000 and 2001
23 January 2001
S-P sales growth driven by Claritin
24 October 2000
Schering-Plough net income up 16%
26 July 2000
Schering-Plough net income rises 16.5%
26 April 2000
Phase III data shows superiority of Enzon's PEG-Intron
19 April 2000
S-P gains CPMP backing for PEG-Intron
24 February 2000
ICN Pharma to boost R&D activities
16 February 2000
First approval of Melacine in Canada
5 November 1999
Schering-Plough strong sales boost EPS
22 October 1999
Stock Commentary New York
30 September 1999
ICN Pharmaceuticals charged with misleading investors
19 August 1999
Rebetol launch in Germany
22 June 1999
Schering-Plough buys $27 mill of ICN stock
9 April 1999
Enzon - improving the delivery and side effect profile of proven
20 January 1999
Medeva Has Heavy Reliance On Hepagene
4 December 1998
AASLD Conference - Focus On HCV/HBV By Lehman
1 December 1998
Alkermes Loses Deals With J&J And S-P
26 November 1998
Enzon's PEG-Intron A In Phase III For CML
23 November 1998
Ribi Withdraws Melacine In EU
5 November 1998
Stock Commentary New York
29 October 1998
Healthy Third-Quarter Growth For US Drug Majors
22 October 1998
Lamivudine Backed For Hep B Approval In USA
8 October 1998
PEG-Intron A in Malignant Melanoma
1 October 1998
Pediatric Appro For Intron A
10 September 1998
Solid Growth Forecast For Schering Plough
24 August 1998
Solid 2nd Qtr For Schering-Plough
22 July 1998
Schering-Plough Still Impressing Analysts
9 July 1998
Schering-Plough Gains Worldwide Melacine Rights
26 June 1998
Stock Commentary New York
15 June 1998
FDA Clears Rebetron, New Therapy For Hepatitis C
15 June 1998
Stock Commentary New York
7 May 1998
Latest Wave Of US 1st Quarter Results
7 May 1998
US Quarterly Financial Results Round-Up
23 April 1998
S-P Files PLA For Intron A Combo Therapy
16 April 1998
Melacine Plus Intron A Trial On Track
26 March 1998
Strong Growth For US Drug Firms In 1997
28 January 1998
Hep C Drug Given Priority Status
22 January 1998
Record 4th Qtr & 1997 Results For Biogen
16 January 1998
S-P Files NDA For Rebetol Plus Intron-A
11 December 1997
S-P Begins Ph II Zadaxin Trials
20 November 1997
S-P's Intron A Approved For NHL
11 November 1997
FDA Panel Backs New Use For Intron A
23 October 1997
New York Stock Comment
23 October 1997
US 3rd Quarter Results Show Strong Growth
22 October 1997
Amgen's Infergen Approved; 1st New Product In 6 Years
9 October 1997
Intron A Plus Ribavirin Improve HCV Outcome
25 September 1997
Biogen Sues Amgen Over Infergen
7 August 1997
Enzon Takes New IFN Alfa Into Phase III
7 August 1997
Solid Growth For US Firms Despite Strong $
24 July 1997
Forex Impacts Sales At Pfizer, Merck And S-P
22 April 1997
Significant Increases For US Drug Firms In 1996
3 February 1997
US 4th Qtr/Year-End Results See Strong Growth
27 January 1997
Major US Drug Cos Post Strong Results In 3rd Qtr
28 October 1996
Single-Digit Profits Growth For B-MS And W-L
5 August 1996
Amgen Licence CIFN Rights To Yamanouchi
24 June 1996
Schering-Plough Forecasts 15% EPS Rise For 1996
10 June 1996
Sales Growth At Yamanouchi Led By Gaster
10 June 1996
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
